nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CYP3A4—Temozolomide—skin cancer	0.167	0.292	CbGbCtD
Solifenacin—CYP3A4—Imiquimod—skin cancer	0.167	0.292	CbGbCtD
Solifenacin—CYP3A4—Vismodegib—skin cancer	0.116	0.202	CbGbCtD
Solifenacin—CYP3A4—Vemurafenib—skin cancer	0.0915	0.16	CbGbCtD
Solifenacin—CYP3A4—Docetaxel—skin cancer	0.0314	0.0548	CbGbCtD
Solifenacin—CHRM3—muscle of abdomen—skin cancer	0.00587	0.351	CbGeAlD
Solifenacin—CHRM5—skin epidermis—skin cancer	0.00384	0.229	CbGeAlD
Solifenacin—Intestinal obstruction—Docetaxel—skin cancer	0.00271	0.00661	CcSEcCtD
Solifenacin—Liver disorder—Docetaxel—skin cancer	0.00271	0.00661	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Vismodegib—skin cancer	0.00271	0.00661	CcSEcCtD
Solifenacin—Fatigue—Vismodegib—skin cancer	0.00271	0.0066	CcSEcCtD
Solifenacin—Oedema peripheral—Vemurafenib—skin cancer	0.00269	0.00656	CcSEcCtD
Solifenacin—Constipation—Vismodegib—skin cancer	0.00269	0.00655	CcSEcCtD
Solifenacin—Connective tissue disorder—Vemurafenib—skin cancer	0.00269	0.00655	CcSEcCtD
Solifenacin—Ileus—Docetaxel—skin cancer	0.00261	0.00637	CcSEcCtD
Solifenacin—Infestation NOS—Imiquimod—skin cancer	0.0026	0.00633	CcSEcCtD
Solifenacin—Infestation—Imiquimod—skin cancer	0.0026	0.00633	CcSEcCtD
Solifenacin—Depression—Imiquimod—skin cancer	0.00259	0.00631	CcSEcCtD
Solifenacin—Erythema multiforme—Vemurafenib—skin cancer	0.00259	0.0063	CcSEcCtD
Solifenacin—Gastrointestinal pain—Vismodegib—skin cancer	0.00257	0.00626	CcSEcCtD
Solifenacin—Dry eye—Temozolomide—skin cancer	0.00257	0.00626	CcSEcCtD
Solifenacin—Eye disorder—Vemurafenib—skin cancer	0.00256	0.00622	CcSEcCtD
Solifenacin—Cardiac disorder—Vemurafenib—skin cancer	0.00254	0.00618	CcSEcCtD
Solifenacin—Urinary tract infection—Imiquimod—skin cancer	0.00252	0.00615	CcSEcCtD
Solifenacin—Abdominal pain—Vismodegib—skin cancer	0.00249	0.00605	CcSEcCtD
Solifenacin—Angiopathy—Vemurafenib—skin cancer	0.00248	0.00604	CcSEcCtD
Solifenacin—Mediastinal disorder—Vemurafenib—skin cancer	0.00246	0.006	CcSEcCtD
Solifenacin—Hepatobiliary disease—Imiquimod—skin cancer	0.00246	0.00598	CcSEcCtD
Solifenacin—Malnutrition—Vemurafenib—skin cancer	0.00238	0.0058	CcSEcCtD
Solifenacin—Dysgeusia—Vemurafenib—skin cancer	0.00233	0.00568	CcSEcCtD
Solifenacin—Pharyngitis—Imiquimod—skin cancer	0.00231	0.00564	CcSEcCtD
Solifenacin—Urinary tract disorder—Imiquimod—skin cancer	0.0023	0.00561	CcSEcCtD
Solifenacin—Connective tissue disorder—Imiquimod—skin cancer	0.00229	0.00558	CcSEcCtD
Solifenacin—Urethral disorder—Imiquimod—skin cancer	0.00229	0.00557	CcSEcCtD
Solifenacin—Asthenia—Vismodegib—skin cancer	0.00226	0.0055	CcSEcCtD
Solifenacin—Pruritus—Vismodegib—skin cancer	0.00222	0.00542	CcSEcCtD
Solifenacin—Erythema multiforme—Imiquimod—skin cancer	0.0022	0.00537	CcSEcCtD
Solifenacin—Eye disorder—Imiquimod—skin cancer	0.00218	0.00531	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Temozolomide—skin cancer	0.00214	0.00521	CcSEcCtD
Solifenacin—Angiopathy—Imiquimod—skin cancer	0.00212	0.00515	CcSEcCtD
Solifenacin—Immune system disorder—Imiquimod—skin cancer	0.00211	0.00513	CcSEcCtD
Solifenacin—Mediastinal disorder—Imiquimod—skin cancer	0.0021	0.00512	CcSEcCtD
Solifenacin—Cough—Vemurafenib—skin cancer	0.00208	0.00506	CcSEcCtD
Solifenacin—Liver function test abnormal—Dactinomycin—skin cancer	0.00206	0.00502	CcSEcCtD
Solifenacin—Mental disorder—Imiquimod—skin cancer	0.00204	0.00498	CcSEcCtD
Solifenacin—Malnutrition—Imiquimod—skin cancer	0.00203	0.00494	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00201	0.0049	CcSEcCtD
Solifenacin—Vomiting—Vismodegib—skin cancer	0.002	0.00487	CcSEcCtD
Solifenacin—Drug interaction—Docetaxel—skin cancer	0.00199	0.00486	CcSEcCtD
Solifenacin—Rash—Vismodegib—skin cancer	0.00198	0.00483	CcSEcCtD
Solifenacin—Dermatitis—Vismodegib—skin cancer	0.00198	0.00482	CcSEcCtD
Solifenacin—Anaphylactic shock—Vemurafenib—skin cancer	0.00194	0.00473	CcSEcCtD
Solifenacin—Infection—Vemurafenib—skin cancer	0.00193	0.0047	CcSEcCtD
Solifenacin—Nervous system disorder—Vemurafenib—skin cancer	0.00191	0.00464	CcSEcCtD
Solifenacin—Skin disorder—Vemurafenib—skin cancer	0.00189	0.0046	CcSEcCtD
Solifenacin—Nausea—Vismodegib—skin cancer	0.00187	0.00455	CcSEcCtD
Solifenacin—Angioedema—Imiquimod—skin cancer	0.00185	0.00452	CcSEcCtD
Solifenacin—Dry skin—Temozolomide—skin cancer	0.00185	0.00451	CcSEcCtD
Solifenacin—Hepatocellular injury—Docetaxel—skin cancer	0.00185	0.00451	CcSEcCtD
Solifenacin—Palpitations—Imiquimod—skin cancer	0.00179	0.00437	CcSEcCtD
Solifenacin—Muscular weakness—Temozolomide—skin cancer	0.00178	0.00434	CcSEcCtD
Solifenacin—Cough—Imiquimod—skin cancer	0.00177	0.00431	CcSEcCtD
Solifenacin—Hypertension—Imiquimod—skin cancer	0.00175	0.00427	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00172	0.00418	CcSEcCtD
Solifenacin—Dry skin—Fluorouracil—skin cancer	0.00171	0.00416	CcSEcCtD
Solifenacin—Dry mouth—Imiquimod—skin cancer	0.00169	0.00412	CcSEcCtD
Solifenacin—Decreased appetite—Vemurafenib—skin cancer	0.00169	0.00411	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00168	0.00409	CcSEcCtD
Solifenacin—Fatigue—Vemurafenib—skin cancer	0.00167	0.00408	CcSEcCtD
Solifenacin—Constipation—Vemurafenib—skin cancer	0.00166	0.00405	CcSEcCtD
Solifenacin—Infection—Imiquimod—skin cancer	0.00165	0.00401	CcSEcCtD
Solifenacin—Muscular weakness—Fluorouracil—skin cancer	0.00164	0.004	CcSEcCtD
Solifenacin—Dysuria—Temozolomide—skin cancer	0.00163	0.00398	CcSEcCtD
Solifenacin—Nervous system disorder—Imiquimod—skin cancer	0.00162	0.00396	CcSEcCtD
Solifenacin—Tachycardia—Imiquimod—skin cancer	0.00162	0.00394	CcSEcCtD
Solifenacin—Skin disorder—Imiquimod—skin cancer	0.00161	0.00392	CcSEcCtD
Solifenacin—Infestation NOS—Temozolomide—skin cancer	0.00156	0.00379	CcSEcCtD
Solifenacin—Infestation—Temozolomide—skin cancer	0.00156	0.00379	CcSEcCtD
Solifenacin—Depression—Temozolomide—skin cancer	0.00155	0.00378	CcSEcCtD
Solifenacin—Pharyngitis—Dactinomycin—skin cancer	0.00153	0.00374	CcSEcCtD
Solifenacin—Urinary tract infection—Temozolomide—skin cancer	0.00151	0.00369	CcSEcCtD
Solifenacin—Somnolence—Imiquimod—skin cancer	0.00147	0.00359	CcSEcCtD
Solifenacin—Hepatobiliary disease—Temozolomide—skin cancer	0.00147	0.00359	CcSEcCtD
Solifenacin—Erythema multiforme—Dactinomycin—skin cancer	0.00146	0.00356	CcSEcCtD
Solifenacin—Dyspepsia—Imiquimod—skin cancer	0.00146	0.00355	CcSEcCtD
Solifenacin—Decreased appetite—Imiquimod—skin cancer	0.00144	0.00351	CcSEcCtD
Solifenacin—Infestation NOS—Fluorouracil—skin cancer	0.00143	0.00349	CcSEcCtD
Solifenacin—Infestation—Fluorouracil—skin cancer	0.00143	0.00349	CcSEcCtD
Solifenacin—Hypersensitivity—Vemurafenib—skin cancer	0.00143	0.00349	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Imiquimod—skin cancer	0.00143	0.00348	CcSEcCtD
Solifenacin—Fatigue—Imiquimod—skin cancer	0.00143	0.00348	CcSEcCtD
Solifenacin—Atrial fibrillation—Docetaxel—skin cancer	0.00142	0.00345	CcSEcCtD
Solifenacin—Renal impairment—Docetaxel—skin cancer	0.00141	0.00344	CcSEcCtD
Solifenacin—Urinary tract infection—Fluorouracil—skin cancer	0.00139	0.0034	CcSEcCtD
Solifenacin—Asthenia—Vemurafenib—skin cancer	0.00139	0.0034	CcSEcCtD
Solifenacin—Hallucination—Temozolomide—skin cancer	0.00139	0.00339	CcSEcCtD
Solifenacin—Pharyngitis—Temozolomide—skin cancer	0.00139	0.00338	CcSEcCtD
Solifenacin—Urinary tract disorder—Temozolomide—skin cancer	0.00138	0.00336	CcSEcCtD
Solifenacin—Oedema peripheral—Temozolomide—skin cancer	0.00138	0.00335	CcSEcCtD
Solifenacin—Pruritus—Vemurafenib—skin cancer	0.00137	0.00335	CcSEcCtD
Solifenacin—Connective tissue disorder—Temozolomide—skin cancer	0.00137	0.00334	CcSEcCtD
Solifenacin—Urethral disorder—Temozolomide—skin cancer	0.00137	0.00334	CcSEcCtD
Solifenacin—Feeling abnormal—Imiquimod—skin cancer	0.00137	0.00333	CcSEcCtD
Solifenacin—Gastrointestinal pain—Imiquimod—skin cancer	0.00135	0.0033	CcSEcCtD
Solifenacin—Erythema multiforme—Temozolomide—skin cancer	0.00132	0.00322	CcSEcCtD
Solifenacin—Urticaria—Imiquimod—skin cancer	0.00132	0.00321	CcSEcCtD
Solifenacin—Abdominal pain—Imiquimod—skin cancer	0.00131	0.00319	CcSEcCtD
Solifenacin—Eye disorder—Temozolomide—skin cancer	0.00131	0.00318	CcSEcCtD
Solifenacin—Cardiac disorder—Temozolomide—skin cancer	0.0013	0.00316	CcSEcCtD
Solifenacin—Dizziness—Vemurafenib—skin cancer	0.00128	0.00313	CcSEcCtD
Solifenacin—Pharyngitis—Fluorouracil—skin cancer	0.00128	0.00311	CcSEcCtD
Solifenacin—Angiopathy—Temozolomide—skin cancer	0.00127	0.00309	CcSEcCtD
Solifenacin—Immune system disorder—Temozolomide—skin cancer	0.00126	0.00307	CcSEcCtD
Solifenacin—Mediastinal disorder—Temozolomide—skin cancer	0.00126	0.00307	CcSEcCtD
Solifenacin—Cough—Bleomycin—skin cancer	0.00126	0.00307	CcSEcCtD
Solifenacin—CHRM5—epithelium—skin cancer	0.00125	0.0746	CbGeAlD
Solifenacin—Liver function test abnormal—Docetaxel—skin cancer	0.00124	0.00302	CcSEcCtD
Solifenacin—Vomiting—Vemurafenib—skin cancer	0.00124	0.00301	CcSEcCtD
Solifenacin—Dry skin—Docetaxel—skin cancer	0.00123	0.003	CcSEcCtD
Solifenacin—Abdominal pain upper—Docetaxel—skin cancer	0.00123	0.00299	CcSEcCtD
Solifenacin—Rash—Vemurafenib—skin cancer	0.00122	0.00298	CcSEcCtD
Solifenacin—Mental disorder—Temozolomide—skin cancer	0.00122	0.00298	CcSEcCtD
Solifenacin—Dermatitis—Vemurafenib—skin cancer	0.00122	0.00298	CcSEcCtD
Solifenacin—Hypersensitivity—Imiquimod—skin cancer	0.00122	0.00297	CcSEcCtD
Solifenacin—Headache—Vemurafenib—skin cancer	0.00122	0.00296	CcSEcCtD
Solifenacin—Malnutrition—Temozolomide—skin cancer	0.00122	0.00296	CcSEcCtD
Solifenacin—Dysgeusia—Temozolomide—skin cancer	0.00119	0.0029	CcSEcCtD
Solifenacin—CHRM5—skin of body—skin cancer	0.00119	0.071	CbGeAlD
Solifenacin—Asthenia—Imiquimod—skin cancer	0.00119	0.0029	CcSEcCtD
Solifenacin—Confusional state—Bleomycin—skin cancer	0.00119	0.00289	CcSEcCtD
Solifenacin—Anaphylactic shock—Bleomycin—skin cancer	0.00118	0.00287	CcSEcCtD
Solifenacin—Pruritus—Imiquimod—skin cancer	0.00117	0.00286	CcSEcCtD
Solifenacin—Infection—Bleomycin—skin cancer	0.00117	0.00285	CcSEcCtD
Solifenacin—Nausea—Vemurafenib—skin cancer	0.00115	0.00281	CcSEcCtD
Solifenacin—Vision blurred—Temozolomide—skin cancer	0.00115	0.00279	CcSEcCtD
Solifenacin—Angioedema—Temozolomide—skin cancer	0.00111	0.00271	CcSEcCtD
Solifenacin—Dizziness—Imiquimod—skin cancer	0.0011	0.00267	CcSEcCtD
Solifenacin—Infection—Dactinomycin—skin cancer	0.00109	0.00266	CcSEcCtD
Solifenacin—Palpitations—Temozolomide—skin cancer	0.00108	0.00262	CcSEcCtD
Solifenacin—Cough—Temozolomide—skin cancer	0.00106	0.00259	CcSEcCtD
Solifenacin—Vision blurred—Fluorouracil—skin cancer	0.00106	0.00257	CcSEcCtD
Solifenacin—Vomiting—Imiquimod—skin cancer	0.00105	0.00257	CcSEcCtD
Solifenacin—Hypertension—Temozolomide—skin cancer	0.00105	0.00256	CcSEcCtD
Solifenacin—Rash—Imiquimod—skin cancer	0.00104	0.00254	CcSEcCtD
Solifenacin—Dermatitis—Imiquimod—skin cancer	0.00104	0.00254	CcSEcCtD
Solifenacin—Headache—Imiquimod—skin cancer	0.00104	0.00253	CcSEcCtD
Solifenacin—Infestation NOS—Docetaxel—skin cancer	0.00104	0.00252	CcSEcCtD
Solifenacin—Infestation—Docetaxel—skin cancer	0.00104	0.00252	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00103	0.00251	CcSEcCtD
Solifenacin—Decreased appetite—Bleomycin—skin cancer	0.00102	0.00249	CcSEcCtD
Solifenacin—Renal failure—Docetaxel—skin cancer	0.00102	0.00248	CcSEcCtD
Solifenacin—Dry mouth—Temozolomide—skin cancer	0.00101	0.00247	CcSEcCtD
Solifenacin—Confusional state—Temozolomide—skin cancer	0.001	0.00244	CcSEcCtD
Solifenacin—Anaphylactic shock—Temozolomide—skin cancer	0.000993	0.00242	CcSEcCtD
Solifenacin—CHRM4—head—skin cancer	0.000993	0.0593	CbGeAlD
Solifenacin—Infection—Temozolomide—skin cancer	0.000986	0.0024	CcSEcCtD
Solifenacin—Nausea—Imiquimod—skin cancer	0.000984	0.0024	CcSEcCtD
Solifenacin—Hepatobiliary disease—Docetaxel—skin cancer	0.000979	0.00238	CcSEcCtD
Solifenacin—Nervous system disorder—Temozolomide—skin cancer	0.000974	0.00237	CcSEcCtD
Solifenacin—Feeling abnormal—Bleomycin—skin cancer	0.00097	0.00236	CcSEcCtD
Solifenacin—Skin disorder—Temozolomide—skin cancer	0.000964	0.00235	CcSEcCtD
Solifenacin—Decreased appetite—Dactinomycin—skin cancer	0.000954	0.00232	CcSEcCtD
Solifenacin—Fatigue—Dactinomycin—skin cancer	0.000946	0.00231	CcSEcCtD
Solifenacin—Urticaria—Bleomycin—skin cancer	0.000935	0.00228	CcSEcCtD
Solifenacin—Confusional state—Fluorouracil—skin cancer	0.000922	0.00225	CcSEcCtD
Solifenacin—Pharyngitis—Docetaxel—skin cancer	0.000922	0.00225	CcSEcCtD
Solifenacin—Urinary tract disorder—Docetaxel—skin cancer	0.000918	0.00224	CcSEcCtD
Solifenacin—Oedema peripheral—Docetaxel—skin cancer	0.000916	0.00223	CcSEcCtD
Solifenacin—Anaphylactic shock—Fluorouracil—skin cancer	0.000915	0.00223	CcSEcCtD
Solifenacin—Connective tissue disorder—Docetaxel—skin cancer	0.000913	0.00222	CcSEcCtD
Solifenacin—Urethral disorder—Docetaxel—skin cancer	0.000911	0.00222	CcSEcCtD
Solifenacin—Infection—Fluorouracil—skin cancer	0.000909	0.00221	CcSEcCtD
Solifenacin—Feeling abnormal—Dactinomycin—skin cancer	0.000905	0.0022	CcSEcCtD
Solifenacin—Gastrointestinal pain—Dactinomycin—skin cancer	0.000898	0.00219	CcSEcCtD
Solifenacin—Nervous system disorder—Fluorouracil—skin cancer	0.000897	0.00219	CcSEcCtD
Solifenacin—Tachycardia—Fluorouracil—skin cancer	0.000893	0.00217	CcSEcCtD
Solifenacin—Somnolence—Temozolomide—skin cancer	0.000883	0.00215	CcSEcCtD
Solifenacin—Erythema multiforme—Docetaxel—skin cancer	0.000879	0.00214	CcSEcCtD
Solifenacin—Dyspepsia—Temozolomide—skin cancer	0.000874	0.00213	CcSEcCtD
Solifenacin—Eye disorder—Docetaxel—skin cancer	0.000868	0.00212	CcSEcCtD
Solifenacin—Abdominal pain—Dactinomycin—skin cancer	0.000868	0.00211	CcSEcCtD
Solifenacin—Hypersensitivity—Bleomycin—skin cancer	0.000867	0.00211	CcSEcCtD
Solifenacin—Decreased appetite—Temozolomide—skin cancer	0.000863	0.0021	CcSEcCtD
Solifenacin—Cardiac disorder—Docetaxel—skin cancer	0.000862	0.0021	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Temozolomide—skin cancer	0.000857	0.00209	CcSEcCtD
Solifenacin—Fatigue—Temozolomide—skin cancer	0.000856	0.00208	CcSEcCtD
Solifenacin—Constipation—Temozolomide—skin cancer	0.000849	0.00207	CcSEcCtD
Solifenacin—Asthenia—Bleomycin—skin cancer	0.000844	0.00206	CcSEcCtD
Solifenacin—Angiopathy—Docetaxel—skin cancer	0.000843	0.00205	CcSEcCtD
Solifenacin—Immune system disorder—Docetaxel—skin cancer	0.000839	0.00204	CcSEcCtD
Solifenacin—Mediastinal disorder—Docetaxel—skin cancer	0.000838	0.00204	CcSEcCtD
Solifenacin—Pruritus—Bleomycin—skin cancer	0.000833	0.00203	CcSEcCtD
Solifenacin—Feeling abnormal—Temozolomide—skin cancer	0.000818	0.00199	CcSEcCtD
Solifenacin—Mental disorder—Docetaxel—skin cancer	0.000814	0.00198	CcSEcCtD
Solifenacin—Somnolence—Fluorouracil—skin cancer	0.000813	0.00198	CcSEcCtD
Solifenacin—Gastrointestinal pain—Temozolomide—skin cancer	0.000812	0.00198	CcSEcCtD
Solifenacin—Malnutrition—Docetaxel—skin cancer	0.000809	0.00197	CcSEcCtD
Solifenacin—Hypersensitivity—Dactinomycin—skin cancer	0.000809	0.00197	CcSEcCtD
Solifenacin—Dyspepsia—Fluorouracil—skin cancer	0.000805	0.00196	CcSEcCtD
Solifenacin—Decreased appetite—Fluorouracil—skin cancer	0.000795	0.00194	CcSEcCtD
Solifenacin—Dysgeusia—Docetaxel—skin cancer	0.000792	0.00193	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00079	0.00192	CcSEcCtD
Solifenacin—Urticaria—Temozolomide—skin cancer	0.000789	0.00192	CcSEcCtD
Solifenacin—Asthenia—Dactinomycin—skin cancer	0.000788	0.00192	CcSEcCtD
Solifenacin—Abdominal pain—Temozolomide—skin cancer	0.000785	0.00191	CcSEcCtD
Solifenacin—CHRM5—head—skin cancer	0.000776	0.0463	CbGeAlD
Solifenacin—Feeling abnormal—Fluorouracil—skin cancer	0.000754	0.00184	CcSEcCtD
Solifenacin—Vomiting—Bleomycin—skin cancer	0.000748	0.00182	CcSEcCtD
Solifenacin—Rash—Bleomycin—skin cancer	0.000742	0.00181	CcSEcCtD
Solifenacin—Dermatitis—Bleomycin—skin cancer	0.000741	0.00181	CcSEcCtD
Solifenacin—Hypersensitivity—Temozolomide—skin cancer	0.000731	0.00178	CcSEcCtD
Solifenacin—Urticaria—Fluorouracil—skin cancer	0.000727	0.00177	CcSEcCtD
Solifenacin—Palpitations—Docetaxel—skin cancer	0.000715	0.00174	CcSEcCtD
Solifenacin—Asthenia—Temozolomide—skin cancer	0.000712	0.00174	CcSEcCtD
Solifenacin—Cough—Docetaxel—skin cancer	0.000706	0.00172	CcSEcCtD
Solifenacin—Pruritus—Temozolomide—skin cancer	0.000702	0.00171	CcSEcCtD
Solifenacin—Nausea—Bleomycin—skin cancer	0.000699	0.0017	CcSEcCtD
Solifenacin—Hypertension—Docetaxel—skin cancer	0.000698	0.0017	CcSEcCtD
Solifenacin—Vomiting—Dactinomycin—skin cancer	0.000698	0.0017	CcSEcCtD
Solifenacin—Rash—Dactinomycin—skin cancer	0.000692	0.00169	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000684	0.00167	CcSEcCtD
Solifenacin—Hypersensitivity—Fluorouracil—skin cancer	0.000674	0.00164	CcSEcCtD
Solifenacin—Dry mouth—Docetaxel—skin cancer	0.000674	0.00164	CcSEcCtD
Solifenacin—Confusional state—Docetaxel—skin cancer	0.000666	0.00162	CcSEcCtD
Solifenacin—Anaphylactic shock—Docetaxel—skin cancer	0.00066	0.00161	CcSEcCtD
Solifenacin—Dizziness—Temozolomide—skin cancer	0.000657	0.0016	CcSEcCtD
Solifenacin—Infection—Docetaxel—skin cancer	0.000656	0.0016	CcSEcCtD
Solifenacin—Nausea—Dactinomycin—skin cancer	0.000652	0.00159	CcSEcCtD
Solifenacin—Nervous system disorder—Docetaxel—skin cancer	0.000647	0.00158	CcSEcCtD
Solifenacin—Pruritus—Fluorouracil—skin cancer	0.000647	0.00158	CcSEcCtD
Solifenacin—Tachycardia—Docetaxel—skin cancer	0.000644	0.00157	CcSEcCtD
Solifenacin—Skin disorder—Docetaxel—skin cancer	0.000641	0.00156	CcSEcCtD
Solifenacin—Vomiting—Temozolomide—skin cancer	0.000631	0.00154	CcSEcCtD
Solifenacin—Rash—Temozolomide—skin cancer	0.000626	0.00152	CcSEcCtD
Solifenacin—Dermatitis—Temozolomide—skin cancer	0.000625	0.00152	CcSEcCtD
Solifenacin—Headache—Temozolomide—skin cancer	0.000622	0.00152	CcSEcCtD
Solifenacin—Dizziness—Fluorouracil—skin cancer	0.000605	0.00147	CcSEcCtD
Solifenacin—Nausea—Temozolomide—skin cancer	0.00059	0.00144	CcSEcCtD
Solifenacin—Somnolence—Docetaxel—skin cancer	0.000587	0.00143	CcSEcCtD
Solifenacin—Vomiting—Fluorouracil—skin cancer	0.000582	0.00142	CcSEcCtD
Solifenacin—Dyspepsia—Docetaxel—skin cancer	0.000581	0.00142	CcSEcCtD
Solifenacin—CHRM1—female reproductive system—skin cancer	0.00058	0.0346	CbGeAlD
Solifenacin—Rash—Fluorouracil—skin cancer	0.000577	0.0014	CcSEcCtD
Solifenacin—Dermatitis—Fluorouracil—skin cancer	0.000576	0.0014	CcSEcCtD
Solifenacin—Decreased appetite—Docetaxel—skin cancer	0.000574	0.0014	CcSEcCtD
Solifenacin—Headache—Fluorouracil—skin cancer	0.000573	0.0014	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Docetaxel—skin cancer	0.00057	0.00139	CcSEcCtD
Solifenacin—Fatigue—Docetaxel—skin cancer	0.000569	0.00139	CcSEcCtD
Solifenacin—Constipation—Docetaxel—skin cancer	0.000565	0.00138	CcSEcCtD
Solifenacin—Feeling abnormal—Docetaxel—skin cancer	0.000544	0.00133	CcSEcCtD
Solifenacin—Nausea—Fluorouracil—skin cancer	0.000543	0.00132	CcSEcCtD
Solifenacin—Gastrointestinal pain—Docetaxel—skin cancer	0.00054	0.00132	CcSEcCtD
Solifenacin—CHRM2—head—skin cancer	0.000533	0.0318	CbGeAlD
Solifenacin—Abdominal pain—Docetaxel—skin cancer	0.000522	0.00127	CcSEcCtD
Solifenacin—CHRM3—female reproductive system—skin cancer	0.000519	0.031	CbGeAlD
Solifenacin—Hypersensitivity—Docetaxel—skin cancer	0.000486	0.00118	CcSEcCtD
Solifenacin—CHRM1—head—skin cancer	0.000485	0.0289	CbGeAlD
Solifenacin—Asthenia—Docetaxel—skin cancer	0.000474	0.00115	CcSEcCtD
Solifenacin—Pruritus—Docetaxel—skin cancer	0.000467	0.00114	CcSEcCtD
Solifenacin—Dizziness—Docetaxel—skin cancer	0.000437	0.00106	CcSEcCtD
Solifenacin—CHRM3—head—skin cancer	0.000434	0.0259	CbGeAlD
Solifenacin—Vomiting—Docetaxel—skin cancer	0.00042	0.00102	CcSEcCtD
Solifenacin—Rash—Docetaxel—skin cancer	0.000416	0.00101	CcSEcCtD
Solifenacin—Dermatitis—Docetaxel—skin cancer	0.000416	0.00101	CcSEcCtD
Solifenacin—Headache—Docetaxel—skin cancer	0.000414	0.00101	CcSEcCtD
Solifenacin—Nausea—Docetaxel—skin cancer	0.000392	0.000955	CcSEcCtD
Solifenacin—CYP3A4—female reproductive system—skin cancer	0.000285	0.017	CbGeAlD
